PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK (SESAME 2)

• ClinicalTrials.gov Identifier: NCT03511326
• Recruitment Status: Completed
• First Posted: April 27, 2018
• Results First Posted: December 10, 2020
• Last Update Posted: December 10, 2020
• Sponsor: Galderma
• Information provided by (Responsible Party): Galderma

Study Description

Brief Summary:

Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin), excluding nose eyelids, lips and mucosa or balding scalp, using Luxerm® DL-PDT treatment.

Condition or disease	Intervention/treatment	Phase
Actinic Keratoses	Drug: Methyl Aminolaevulinate 16% Cream	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 50 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp
• Actual Study Start Date: June 7, 2017
• Actual Primary Completion Date: November 28, 2017
• Actual Study Completion Date: November 28, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Luxerm®	Drug: Methyl Aminolaevulinate 16% Cream; Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy; Other Name: 160mg/g of methyl aminolevulinate

Outcome Measures

Primary Outcome Measures :

1. Overall Subject Satisfaction the Day of Treatment After Daylight Session [ Time Frame: the day of treatment after daylight session ]
   Percentage of subjects satisfied and very satisfied globally with Luxerm Daylight procedure, the day of treatment after daylight session
2. Overall Subject Satisfaction at Week 12 Post-treatment [ Time Frame: Week 12 ]
   Percentage of subjects satisfied or very satisfied (overall) with Luxerm DL procedure

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female age > 18 years old.
2. Subject with at least 5 clinically confirmed thin or non-hyperkeratotic and non-pigmented actinic keratoses in an anatomical area on the face (e.g., forehead or cheek or chin) excluding nose, eyelids, lips and mucosa, or balding scalp, at baseline visit.
3. Subject or caregiver capable of performing the skin preparation and Luxerm® treatment application as per the investigator instructions.
4. Female subject of childbearing potential must have a negative UPT at baseline (UPT should have a sensitivity of 25 IU/L or less) and agree to be strictly abstinent or use a highly effective method of birth control during the study (i.e. progestogen-only oral hormonal contraception; male or female condom; cap, diaphragm or sponge with spermicide; bilateral tubal ligation; combined (estrogen and progestogen-containing) oral hormonal contraception, or injectable or implants hormonal contraception (at a stable dose for at least 1 month prior to baseline); intra-uterine devices inserted at least 1 month prior to baseline; vasectomized partner for at least 3 months prior to baseline).
5. Female subject of non-childbearing potential, e.g.: post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy or bilateral ovariectomy.
6. Subject has read and signed the approved informed consent form (ICF) prior to any participation in the study.
7. Subject has read and signed a Photograph Release Consent Form if he/she is willing to be photographed.
8. Subject (or caregiver) willing and able to comply with all of the time commitments and procedural requirements of the clinical trial protocol.

Exclusion Criteria:

1. Subject with a clinical diagnosis of a skin disease other than AK (including non-melanoma skin cancer) on the target anatomical area.
2. Subject with severe AK (thick, hyperkeratotic AK) per anatomical area (face or scalp).
3. Subject with clinical diagnosis of other skin disease on the target anatomical area.
4. Subject with pigmented AK on the target anatomical area.
5. Subject with melanoma at any location.
6. Immunocompromised subject or requiring immunosuppressive therapies.
7. Subject with porphyria; photosensitivity- related disorders, active infectious disease.
8. Subject with known or suspected hypersensitivity to the active substance or to any excipients of Luxerm® (see Summary of Product Characteristics).
9. Female subject who is pregnant, nursing or planning a pregnancy during the study.
10. Subject who has used any of the following topical preparations on the area to be treated: keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g. glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment.

11. Subject with a wash-out period from baseline for topical or systemic treatment or medical/surgical procedure in the anatomical area (for AKs) less than the following:

    • Retinoids, including tazarotene, adapalene, tretinoin, retinol ==> 4 weeks
    • Cryotherapy, diclofenac, corticosteroids or other treatments for AK==> 8 weeks
    • Microdermabrasion, laser ablative treatments or chemical peels ==>8 weeks
    • 5-FU, imiquimod ==>24 weeks
    • Surgical: excision and reconstructive surgery, chemosurgery, ==>12 weeks
    • Any Photodynamic Therapy, ingenol mebutate (Pep-005), Radiotherapy and UV radiation therapy==>12 weeks
    • Investigational therapies for Actinic Keratoses==>12 weeks
    • Immunosuppressive drugs (such as glucocorticoids, cytostatic, antibodies, drugs acting on interferon, opioids, TNF binding proteins, Mycophenolate, small biologics agents)==>12 weeks
12. Subject who is currently participating to/ or who has participated in another investigational treatment or device research study within 4 weeks of baseline visit.
13. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
14. Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
15. Subject who is unwilling to refrain from use of prohibited medication during the clinical trial (see section 4.3.5).
16. Subject who is vulnerable (such as deprived of freedom) as defined in Section 1.61 of the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP).
17. Subject with clinically significant abnormal laboratory finding (if any available report) at the baseline visit or medical/surgical condition (other than for actinic keratoses), which might, in the Investigator's opinion, interfere with study evaluations or pose a risk to subject safety during the study.
18. The subject is a study site staff member (investigator, study nurse, etc.) or a relative of one.
19. Subjects with any condition that may be associated with a risk of poor protocol compliance

Contacts and Locations

Locations

Germany

University Hospital Regensburg

Regensburg, Germany

Sponsors and Collaborators

Galderma

Investigators

• Study Director: Rajeev CHAVDA, MD; Galderma

  Study Documents (Full-Text)

Documents provided by Galderma:

Study Protocol and Statistical Analysis Plan  [PDF] February 22, 2017

More Information

• Responsible Party: Galderma
• ClinicalTrials.gov Identifier: NCT03511326
• Other Study ID Numbers: RD.03.SPR.114384
• First Posted: April 27, 2018
• Results First Posted: December 10, 2020
• Last Update Posted: December 10, 2020
• Last Verified: September 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Galderma:

field-treatment

Additional relevant MeSH terms:

Keratosis, Actinic; Keratosis; Skin Diseases; Precancerous Conditions; Neoplasms; Aminolevulinic Acid; Methyl 5-aminolevulinate; Photosensitizing Agents; Dermatologic Agents